Rivaroxaban—Once daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: Rationale and Design of the ROCKET AF study

Unknown author(s)

American Heart Journal · 2010 · 478 citations · 33 references

Concepts

References

33